Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.4%. By the end of trading, Regeneron Pharmaceuticals rose $9.23 (3.5%) to $276.80 on average volume. Throughout the day, 794,797 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 751,500 shares. The stock ranged in a price between $267.91-$277.48 after having opened the day at $267.91 as compared to the previous trading day's close of $267.57. Other companies within the Health Care sector that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 53.7%, Neuralstem ( CUR), up 18.4%, Chimerix ( CMRX), up 16.7% and Receptos ( RCPT), up 14.4%.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $26.0 billion and is part of the drugs industry. Shares are up 56.4% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.